Neuronetics to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders, has announced its plans to release second quarter 2024 financial and operating results before the market opens on Monday, August 12th, 2024. The company will host a conference call to discuss these results at 8:30 a.m. Eastern Time on the same day.
Investors and interested parties can access the conference call via a live webcast in listen-only mode. Additionally, participants have the option to register for the call to listen via telephone. It is recommended that attendees join 10 minutes prior to the event start time.
Neuronetics, Inc. (NASDAQ: STIM), un'azienda di tecnologia medica specializzata in disturbi neuro-salutari, ha annunciato i suoi piani per pubblicare i risultati finanziari e operativi del secondo trimestre del 2024 prima dell'apertura del mercato di lunedì 12 agosto 2024. L'azienda ospiterà una conferenza telefonica per discutere di questi risultati alle 8:30 ora orientale dello stesso giorno.
Investitori e parti interessate possono accedere alla conferenza telefonica tramite una diretta web in modalità ascolto. Inoltre, i partecipanti hanno la possibilità di registrarsi per ascoltare la chiamata via telefono. Si consiglia di unirsi almeno 10 minuti prima dell'inizio dell'evento.
Neuronetics, Inc. (NASDAQ: STIM), una empresa de tecnología médica especializada en trastornos de neuro salud, ha anunciado sus planes para publicar los resultados financieros y operativos del segundo trimestre de 2024 antes de la apertura del mercado el lunes 12 de agosto de 2024. La compañía llevará a cabo una conferencia telefónica para discutir estos resultados a las 8:30 a.m. hora del Este del mismo día.
Los inversionistas y partes interesadas pueden acceder a la conferencia telefónica a través de una transmisión en vivo en modo solo escucha. Además, los participantes tienen la opción de registrarse para escuchar la llamada por teléfono. Se recomienda que los asistentes se unan 10 minutos antes de la hora de inicio del evento.
Neuronetics, Inc. (NASDAQ: STIM), 신경 건강 장애를 전문으로 하는 의료 기술 회사가 2024년 2분기 재무 및 운영 결과를 2024년 8월 12일 월요일 시장 개장 전에 발표할 계획을 발표했습니다. 회사는 같은 날 동부 표준시 오전 8시 30분에 이러한 결과를 논의하기 위한 컨퍼런스 콜을 주최할 예정입니다.
투자자와 이해관계자는 듣기 전용 모드로 라이브 웹캐스트를 통해 컨퍼런스 콜에 접근할 수 있습니다. 추가로, 참가자는 전화로 청취하기 위해 콜에 등록할 수 있는 옵션이 있습니다. 참석자는 이벤트 시작 시간 10분 전에 참여하는 것이 권장됩니다.
Neuronetics, Inc. (NASDAQ: STIM), une entreprise de technologie médicale spécialisée dans les troubles de la neuro-santé, a annoncé son intention de publier les résultats financiers et opérationnels du deuxième trimestre 2024 avant l'ouverture du marché le lundi 12 août 2024. L'entreprise organisera une conférence téléphonique pour discuter de ces résultats à 8h30, heure de l'Est, le même jour.
Les investisseurs et les parties intéressées pourront accéder à la conférence téléphonique par le biais d'un webinaire en direct en mode écoute seule. De plus, les participants ont la possibilité de s'inscrire pour écouter l'appel par téléphone. Il est recommandé aux participants de se connecter 10 minutes avant le début de l'événement.
Neuronetics, Inc. (NASDAQ: STIM), ein Medizintechnikunternehmen, das sich auf neurogesundheitliche Störungen spezialisiert hat, hat seine Pläne bekannt gegeben, die finanziellen und operativen Ergebnisse des zweiten Quartals 2024 vor Markteröffnung am Montag, den 12. August 2024 zu veröffentlichen. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um diese Ergebnisse zu diskutieren.
Investoren und interessierte Parteien können die Konferenz über einen Live-Webcast im Nur-Zuhörer-Modus verfolgen. Darüber hinaus haben die Teilnehmer die Möglichkeit, sich für den Anruf zu registrieren, um telefonisch zuzuhören. Es wird empfohlen, dass sich die Teilnehmer 10 Minuten vor Beginn der Veranstaltung einwählen.
- None.
- None.
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2024 financial and operating results prior to market open on Monday, August 12th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/xsxbsaxh. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. In the United States, NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar is also indicated as a first-line, adjunct for MDD in adolescents 15 and older. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 6.4 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.
Investor Contact
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
FAQ
When will Neuronetics (STIM) release its Q2 2024 financial results?
What time is Neuronetics' (STIM) Q2 2024 earnings call scheduled for?
How can investors access Neuronetics' (STIM) Q2 2024 earnings call?
What is the focus of Neuronetics (STIM) as a company?
